IL17A and Bartsocas-Papas syndrome 1: Clinical data showed that BPs-treated osteoporotic patients have significantly decreased levels of IL-6, IL-17, IL-23, and IFN-γ and a significant increase in IL-4, IL-10, and TGF-β compared to osteoporotic patients who did not receive BPs treatment.